{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:50:53Z","timestamp":1788288653639,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.urolonc.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T12:55:53Z","timestamp":1712840153000},"page":"221.e9-221.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette\u2013Gu\u00e9rin for the treatment of upper tract carcinoma in situ"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-4301","authenticated-orcid":false,"given":"Ian M.","family":"McElree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Y.","family":"Hougen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.03.012_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.012_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.03.012_bib0003","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. [updated: 2023 Nov 16; cited 2024 Jan 20]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.012_bib0004","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with Bacillus Calmette\u2013Gu\u00e9rin in patients with non\u2013muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.03.012_bib0005","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0006","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.21037\/tau.2019.11.09","article-title":"Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma","volume":"9","author":"Metcalf","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.012_bib0007","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2024.03.012_bib0008","unstructured":"Roupr\u00eat M, Gontero P, Birtle A, et al. EAU guidelines on upper urinary tract urothelial cell carcinoma. Accessed October 19, 2023. https:\/\/uroweb.org\/guidelines\/upper-urinary-tract-urothelial-cell-carcinoma\/chapter\/disease-management#note_219"},{"issue":"6","key":"10.1016\/j.urolonc.2024.03.012_bib0009","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO Guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.012_bib0010","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.012_bib0011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for Bacillus Calmette\u2013Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.012_bib0012","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus Calmette\u2013Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: A randomized phase 3 trial of intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve high-grade non\u2013muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette\u2013Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2024.03.012_bib0015","doi-asserted-by":"crossref","unstructured":"Milbar N, Kates M, Chappidi MR, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 3(4):293-303. 10.3233\/BLC-170126","DOI":"10.3233\/BLC-170126"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.012_bib0016","doi-asserted-by":"crossref","first-page":"20.e9","DOI":"10.1016\/j.urolonc.2023.08.013","article-title":"Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma","volume":"42","author":"McElree","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.03.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/472831","article-title":"Review of topical treatment of upper tract urothelial carcinoma","volume":"2009","author":"Nepple","year":"2009","journal-title":"Adv Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.03.012_bib0018","doi-asserted-by":"crossref","first-page":"670.e7","DOI":"10.1016\/j.urolonc.2017.07.024","article-title":"Quadruple immunotherapy of Bacillus Calmette\u2013Gu\u00e9rin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.03.012_bib0019","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1442-2042.2012.03089.x","article-title":"Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer","volume":"19","author":"Lightfoot","year":"2012","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0020","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.21037\/tau.2019.12.25","article-title":"Perioperative complications and adverse sequelae of radical nephroureterectomy","volume":"9","author":"Levy","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.012_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2009.10.004","article-title":"A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma","volume":"75","author":"Jeldres","year":"2010","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0022","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.03.012_bib0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant Bacillus Calmette\u2013Gu\u00e9rin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.urolonc.2024.03.012_bib0024","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/end.2012.0229","article-title":"Outcomes of intrarenal Bacillus Calmette\u2013Gu\u00e9rin\/interferon-\u03b12B for biopsy-proven upper-tract carcinoma in situ","volume":"26","author":"Shapiro","year":"2012","journal-title":"J Endourol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.012_bib0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): Systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12032-018-1102-y","article-title":"Impact of Bacillus Calmette\u2013Gu\u00e9rin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy","volume":"35","author":"Horiguchi","year":"2018","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.012_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/07357907.2018.1430815","article-title":"Efficacy and tolerability of Bacillus Calmette\u2013Gu\u00e9rin therapy as the first-line therapy for upper urinary tract carcinoma in situ","volume":"36","author":"Tomisaki","year":"2018","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.urolonc.2024.03.012_bib0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)36117-7","article-title":"Intrarenal Bacillus Calmette\u2013Guerin therapy for upper urinary tract carcinoma in situ","volume":"149","author":"Sharpe","year":"1993","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.03.012_bib0029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1442-2042.2006.01312.x","article-title":"Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus Bacillus Calmette\u2013Gu\u00e9rin therapy","volume":"13","author":"Kojima","year":"2006","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.03.012_bib0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.juro.2016.03.194","article-title":"Upper urinary tract carcinoma in situ: current knowledge, future direction","volume":"197","author":"Redrow","year":"2017","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.03.012_bib0031","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.03.012_bib0032","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette\u2013Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:00:23Z","timestamp":1715756423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924003971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1078143924003971"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette\u2013Gu\u00e9rin for the treatment of upper tract carcinoma in situ","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}